Reduced expression of miR-200 family members contributes to antiestrogen resistance in LY2 human breast cancer cells TT Manavalan, Y Teng, LM Litchfield, P Muluhngwi, N Al-Rayyan, ... PloS one 8 (4), e62334, 2013 | 115 | 2013 |
Roles for miRNAs in endocrine resistance in breast cancer P Muluhngwi, CM Klinge Endocrine-related cancer 22 (5), R279, 2015 | 87 | 2015 |
Identification of miRNAs as biomarkers for acquired endocrine resistance in breast cancer P Muluhngwi, CM Klinge Molecular and cellular endocrinology 456, 76-86, 2017 | 44 | 2017 |
Tamoxifen differentially regulates miR-29b-1 and miR-29a expression depending on endocrine-sensitivity in breast cancer cells P Muluhngwi, A Krishna, SL Vittitow, JT Napier, KM Richardson, M Ellis, ... Cancer letters 388, 230-238, 2017 | 42 | 2017 |
Nuclear respiratory factor-1 and bioenergetics in tamoxifen-resistant breast cancer cells BN Radde, MM Ivanova, HX Mai, N Alizadeh-Rad, K Piell, P Van Hoose, ... Experimental cell research 347 (1), 222-231, 2016 | 41 | 2016 |
The miR-29 transcriptome in endocrine-sensitive and resistant breast cancer cells P Muluhngwi, N Alizadeh-Rad, SL Vittitow, TS Kalbfleisch, CM Klinge Scientific reports 7 (1), 5205, 2017 | 38 | 2017 |
Transcriptomic response of breast cancer cells to anacardic acid DJ Schultz, A Krishna, SL Vittitow, N Alizadeh-Rad, P Muluhngwi, ... Scientific reports 8 (1), 8063, 2018 | 37 | 2018 |
Genome-wide miRNA response to anacardic acid in breast cancer cells DJ Schultz, P Muluhngwi, N Alizadeh-Rad, MA Green, EC Rouchka, ... PloS one 12 (9), e0184471, 2017 | 23 | 2017 |
Identification and roles of miR-29b-1-3p and miR29a-3p-regulated and non-regulated lncRNAs in endocrine-sensitive and resistant breast cancer cells P Muluhngwi, CM Klinge Cancers 13 (14), 3530, 2021 | 16 | 2021 |
Cell-free DNA diagnostics: current and emerging applications in oncology P Muluhngwi, R Valdes Jr, R Fernandez-Botran, E Burton, B Williams, ... Pharmacogenomics 20 (05), 357-380, 2019 | 14 | 2019 |
Verification of newly FDA-approved kappa and lambda free light chain assays on a previously untested platform P Muluhngwi, CN Sharp, N Pozzi, RJ Elin, SA Jortani Journal of Applied Laboratory Medicine 4 (3), 323-330, 2019 | 8 | 2019 |
Regulation of miR-29b-1/a transcription and identification of target mRNAs in CHO-K1 cells P Muluhngwi, K Richardson, J Napier, EC Rouchka, JL Mott, CM Klinge Molecular and cellular endocrinology 444, 38-47, 2017 | 8 | 2017 |
A shared diagnostic stewardship approach toward improving autoimmune encephalopathy send-out testing utilization CN Sharp, A Fletcher, P Muluhngwi, J Snyder, MW Linder, SA Jortani The Journal of Applied Laboratory Medicine 6 (2), 387-396, 2021 | 2 | 2021 |
Development of de novo donor‐specific antibodies in renal transplant recipients with BK viremia managed with immunosuppression reduction R Hod‐Dvorai, R Lee, P Muluhngwi, M Raijmakers, A Shetty, AR Tambur, ... Transplant Infectious Disease 25 (1), e13993, 2023 | 1 | 2023 |
Development of De Novo Antibody in Renal Transplant Recipients with BK Viremia Managed with Immunosuppression Reduction RH Dvorai, R Lee, P Muluhngwi, M Raijmakers, A Shetty, A Tambur, ... AMERICAN JOURNAL OF TRANSPLANTATION 21, 454-455, 2021 | 1 | 2021 |
P610 Donor specific antibodies (DSA) monitoring: The effect of clinical decision support (CDS) intervention on DSA orders C Scalf, M Greenwood, P Muluhngwi Human Immunology 84, 166, 2023 | | 2023 |
P516 A case of false positive Class II antibody reactivity consistent in both the One Lambda and Immucor Luminex single-antigen bead (SAB) assays P Muluhngwi, A Mollner, H Miller Human Immunology 84, 140, 2023 | | 2023 |
Human Leukocyte Antigens and Transplantation P Muluhngwi, G Tumer Human Leukocyte Antigens-Updates and Advances, 2023 | | 2023 |
HLA and Transplantation P Muluhngwi, G Tumer IntechOpen, 2023 | | 2023 |
ASSESSING THE PERFORMANCE OF THREE HLA ANTIBODY ASSAYS IN EVALUATING TRANSPLANT PATIENTS JD Hoekstra, H Miller, C Scalf, D Maurer, P Muluhngwi HUMAN IMMUNOLOGY 83, 161-161, 2022 | | 2022 |